Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Return on Capital Employed (2018 - 2025)

Dianthus Therapeutics has reported Return on Capital Employed over the past 7 years, most recently at 0.33% for Q3 2025.

  • Quarterly results put Return on Capital Employed at 0.33% for Q3 2025, down 9.0% from a year ago — trailing twelve months through Sep 2025 was 0.33% (down 9.0% YoY), and the annual figure for FY2024 was 0.39%, changed 0.0%.
  • Return on Capital Employed for Q3 2025 was 0.33% at Dianthus Therapeutics, up from 0.41% in the prior quarter.
  • Over the last five years, Return on Capital Employed for DNTH hit a ceiling of 0.03% in Q2 2023 and a floor of 0.53% in Q1 2022.
  • Median Return on Capital Employed over the past 4 years was 0.27% (2023), compared with a mean of 0.27%.
  • Biggest five-year swings in Return on Capital Employed: soared 51bps in 2023 and later decreased -22bps in 2024.
  • Dianthus Therapeutics' Return on Capital Employed stood at 0.18% in 2022, then tumbled by -56bps to 0.27% in 2023, then fell by -8bps to 0.29% in 2024, then fell by -11bps to 0.33% in 2025.
  • The last three reported values for Return on Capital Employed were 0.33% (Q3 2025), 0.41% (Q2 2025), and 0.34% (Q1 2025) per Business Quant data.